NCT05931757View on ClinicalTrials.gov

A Study of Olverembatinib Combined With Blinatumomab in the Treatment of Ph+ ALL

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

July 1, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2030

Conditions
Philadelphia-Positive ALL
Interventions
DRUG

Olverembatinib

Olverembatinib will be taken 40mg qod from the time of diagnosis, and Blinatumomab will be given intravenously up to five cycles.

Trial Locations (1)

215000

First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
lead

The First Affiliated Hospital of Soochow University

OTHER